Stock Alert: AIM ImmunoTech Shares Jump 30% In Premarket

(RTTNews) - Shares of AIM ImmunoTech Inc. (AIM) are rising over 30% in pre-market today, after the company announced that the U.S. FDA has authorized the first human trial assessing the safety and effectiveness of the company's lead asset, Ampligen (rintatolimod), in combination with interferon alfa-2b, in cancer patients with COVID-19, the disease caused by the SARS-CoV-2 coronavirus.

The stock has been trading in the range of $0.38 - $7.50 for the past one year, and closed Wednesday's trade at $2.35, down 5 cents or 2.08%. Trading volume was 6.69 million versus an average volume of 7.85 million shares. AIM is currently trading at $3.06, up 72 cents or 30.49% in the pre-market session.